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Private Limited, Mumbai, IndiaA B S T R A C TObjective: The objective of this study was to quantify the direct
medical and nonmedical costs of stroke among patients with non-
valvular atrial ﬁbrillation in India. Methods: An observational, multi-
center cost-of-illness study was conducted within large tertiary care
hospitals across three metropolitan cities in India. Medical chart
records of eligible patients who were hospitalized during the study
period were reviewed. A standardized data collection form was
designed and used to capture resources expended in the treatment
and management of stroke during the inpatient stay. In addition,
direct medical and nonmedical outpatient care resources and infor-
mal care burden were captured using a detailed questionnaire,
following the patients’ discharge. Factors associated with acute care
costs were investigated using multivariate linear regression analysis.
Results: Data were collected on a total of 400 patients with incident
strokes. Their mean age was 61.4  9.4 years. About 84% of thesee front matter Copyright & 2014, International S
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ndence to: Shalaka Marfatia, pharmEDGE, 49 Circlepatients were diagnosed with ischemic stroke. On average, patients
spent 16  10 days in the hospital. Total mean direct health care costs
per patient amounted to `504,973 (US $8,020) during the ﬁrst year, with
about 47% (mean `235,471; US $3,750) of the total costs due to the
index hospitalization. The modiﬁed Rankin scale score was strongly
associated with costs, whereby severely disabled patients had 32%
higher costs (P ¼ 0.001) compared with moderately disabled patients
during the ﬁrst 3 months postdischarge. Conclusions: Overall, the
ﬁnancial burden associated with medical care for patients with stroke
with atrial ﬁbrillation along with rehabilitation and long-term care
costs places a signiﬁcant demand on health services in India.
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Stroke occurs when interruption of blood supply or leakage of
blood from a blood vessel causes damage to the brain [1]. Every
year, 20 million people worldwide experience a stroke, making it
one of the fastest growing causes of morbidity and mortality [1–
5]. Stroke is a predisposing factor for epilepsy, falls, and depres-
sion [3] and is a leading cause of functional impairments, with
20% of the survivors requiring institutional care after 3 months
and about 15% to 30% permanently disabled [6]. Stroke is no
longer considered a condition that affects the developed world.
Globally, 12.6 million people suffer moderate to severe disability
after stroke and of this, 8.9 million people are from low- and
middle-income countries [3]. Low- and middle-income countries
in the Asia-Paciﬁc region account for 85.5% of total stroke deaths
worldwide, and the number of disability-adjusted life-years in
these countries is reported to be seven times that observed in
high-income countries [7]. It is estimated that in India alone
about 6.36 million disability-adjusted life-years are lost because
of stroke [8].China and India have the largest populations in the Asia-
Paciﬁc region and account for the highest numbers of deaths
from stroke (18,16,000 and 7,27,900, respectively) [9,10]. The
prevalence of stroke in India is reported to be 99 to 222 per
100,000 [10], with about 1.44 to 1.64 million cases of new stroke
diagnosed every year [3,11]. Furthermore, studies have reported
that the average age of patients with stroke in developing
countries is 15 years less than that in developed countries [12].
Results from studies conducted in India have shown that
about 10% to 15% of strokes occur in people younger than 40
years, with about 21% to 48% of strokes being caused by
atherosclerotic large artery occlusive diseases [11,13]. Although
stroke mortality rates are declining or stabilizing in developed
countries, experts are concerned about the emerging epidemic
of stroke in India [14]. As life expectancy is projected to in-
crease, India will likely face a signiﬁcant socioeconomic burden
to meet the cost of managing stroke [15]. A recent study identi-
ﬁed that 7% of medical and 45% of neurological admissions
were due to stroke, with a fatality rate of 9% at hospital discharge
[16].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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[17–20]. Compared with the general population, people with AF
have a ﬁvefold increased risk of stroke [17,18]. AF is responsible for
about 20% of ischemic strokes [17–20]. The risk of stroke in patients
with AF increases with age and with the addition of other risk
factors (e.g., high blood pressure, age 4 75 years, congestive heart
failure, previous stroke or transient ischemic attack or throm-
boembolism, and diabetes) [21–23]. AF-related strokes are predom-
inantly cardioembolic, more severe, and cause greater disability and
have worse outcomes (20% likelihood of death and 60% disability)
than does stroke in people without AF [17–20,24,25]. Given that AF-
related strokes tend to be more severe, they result in higher direct
medical patient cost annually compared with non-AF–related
stroke. The total societal burden of AF-related stroke reaches €13.5
billion per year in the European Union alone [26,27]. Furthermore,
this ﬁnancial burden is higher for patients and their families in
countries such as India where there is a greater level of out-of-
pocket expenditure on health care.
Cost-of-illness studies highlight the economic magnitude of an
illness/condition on society or a part of society. These studies have
been frequently used by policymakers such as the National Insti-
tutes of Health and the Centers for Disease Control and Prevention
in the United States and have been used in part to describe resource
allocations for various diseases [28]. Because limited data are
available regarding resource utilization and costs associated with
the management of stroke in India, the objective of the current
study was to estimate the average direct medical and nonmedical
costs of stroke among patients with nonvalvular AF.Methods
Study Overview
An observational, multicenter cost-of-illness study was con-
ducted at hospitals offering specialty services in neurology across
three metropolitan cities, namely, Gurgaon, Mumbai, and Banga-
lore in India. Based on the Sancd report (2008), these cities had
reported a high prevalence of stroke cases. A site feasibility
analysis was conducted in each city, and chief medical ofﬁcers
from hospitals that met the study criteria were contacted to
understand their interest in participating in the study. Hospitals
were selected on the basis of factors such as bed size, presence of
neurology/stroke unit ward, availability and access to patient
medical charts and discharge records, ethics committee approval
process, and willingness of the key opinion leader and hospital to
participate in the study. Hospitals that consented to participate in
the study were the Holy Family, Saifee, and Lilavati hospitals in
Mumbai; St. John’s Medical College in Bangalore; and the Med-
anta Institute of Neurosciences in Gurgaon. The study was
conducted from a societal perspective and was approved by the
hospital ethics committee board at each participating center. All
participating patients completed an informed consent form at
the start of the study.
Patient inclusion criteria for the study were as follows:
diagnosis of ischemic or hemorrhagic stroke (primary and recur-
rent) for patients older than 18 years, a prior diagnosis of AF, AF
with at least one additional risk factor (i.e., previous ischemic
stroke, transient ischemic attack, or systemic embolism, left
ventricular dysfunction, age Z65 years, with either diabetes
mellitus, history of coronary artery disease, or hypertension).
Patients were excluded from the study on the basis of evidence of
any of the following conditions: 1) cancers, fatal renal, hepatic, or
respiratory insufﬁciency; 2) disabling and progressive neurolog-
ical diseases (multiple sclerosis, Parkinson’s disease); 3) demen-
tia; and 4) refusal or withdrawal of patient informed consent to
participate in the study.Medical chart records of patients who met the above inclusion
criteria and were hospitalized from January 1, 2010, through
December 31, 2011, were reviewed. A standardized data collection
form was designed to capture demographic and clinical charac-
teristics of patients and resources expended for the treatment
and management of stroke during their inpatient stay from
patient medical charts. The data collection form captured infor-
mation on the following parameters: patient demographic char-
acteristics, medical history/comorbid conditions,
pharmacological management, surgery, diagnostic/laboratory
tests, and hospital length of stay (LOS). Because India is predom-
inantly an out-of-pocket payer market, there are limited data, if
any, available on hospital charges; therefore, hospital costs were
derived from per patient billing records at each site. All prices are
2012 values. A trained on-site reviewer performed data collection
at each participating center. All case report forms were veriﬁed
for completeness and accuracy of data. Data collected for the
study were de-identiﬁed and kept conﬁdential at an onsite
password-protected secure server.
Structured interviews using the modiﬁed Rankin Scale (mRS)
[29] were conducted to assess the functional disability due to
stroke among all participating patients within 1 week of hospital
discharge. The mRS is a global disability scale used to measure
the degree of disability or dependence in daily activities of people
who have suffered a stroke or have other neurological disabilities.
It is a commonly used clinical outcome measure for stroke in
clinical trials with a scale from 0 to 6, where 0 indicates “no
symptoms” (perfect health) and 6 indicates “death.”
Because no data were available regarding outpatient resource
use and cost associated with stroke postdischarge, two question-
naires—one to be completed by participating patients and the
other to be completed by physicians—were developed. Patients
who met the inclusion criteria and agreed to participate in the
study completed the questionnaire at 3 months postdischarge via
telephonic or face-to-face interviews. The questionnaire captured
information regarding the frequency of clinic visits with neurol-
ogists, cardiologists, or general practitioners, laboratory and
imaging tests, rehabilitation services (physiotherapy, speech
therapy, etc.), specialized nurse services, additional stroke-
related hospitalizations, and stroke-related medications (name,
dose, and frequency were obtained by asking the patients to refer
to their prescription records). Patients were also requested to
provide estimates for travel costs incurred to obtain medical
services and modiﬁcations made to their home poststroke during
this period. Patients receiving informal care from caregivers were
requested to estimate the cost of informal care on the basis of the
number of days of lost productivity (unpaid leave) by the care-
giver. Outpatient cost for each patient was estimated by multi-
plying the average cost for each resource unit by its frequency for
the acute 3-month period postdischarge.
The physician questionnaire captured data for outpatient
services such as the frequency of outpatient clinic visits, labo-
ratory and imaging tests, and stroke-related medications over the
remaining 9 months after the “acute phase.” This questionnaire
was completed by ﬁve neurologists from the three cities where
the study was conducted. Outpatient costs for this period were
calculated by multiplying the average per visit/service costs by
the total number of visits/services used over the 9-month period.
While estimating the annual costs in the study we assumed that
no patient had a recurrent stroke event during the study period.
Table 1 shows a list of health resource items investigated and
outlines the resources that were estimated in the study.
Statistical Analyses
Statistical analyses were conducted with SPSS version 19.0.
Descriptive analyses were used to describe the continuous and
Table 1 – List of health resource items investigated.
Category List of health resource item Source of data
Inpatient services during index
hospitalization
Length of hospital stay (ICU, general ward) Patient medical chart
recordsSurgery/procedure
Imaging and laboratory tests
Medications
Rehabilitation services (physiotherapy, speech therapy, occupational
therapy, etc.)
Emergency transport (ambulance, taxi, etc.)
Outpatient services postdischarge
(3 mo)
Consultation visits: general physician, neurologists, cardiologists Patient questionnaire
Imaging and laboratory tests
Medications
Rehabilitation services (physiotherapy, speech therapy, occupational
therapy, etc.)
Nursing home/paid nursing services
Home modiﬁcations
Informal care (days of lost productivity)
Transport costs (taxi)
Outpatient services from 3 to 12 mo Consultation visits: general physician, neurologists, cardiologists Physician questionnaire
Imaging and laboratory tests
Medications
Rehabilitation services (physiotherapy, speech therapy, etc.)
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ment during index hospitalization and the follow-up period in
relation to sociodemographic and clinical characteristics, we
performed a series of bivariate analyses using nonparametric
tests (Mann-Whitney and Kruskal-Wallis). Multivariate linear
regression analyses were performed to determine factors signiﬁ-
cantly associated with costs incurred by patients with stroke
during the acute phase. Variables investigated were age, sex,
major clinical events in the patient’s history, stroke risk factors,
and disability level (mRS score). Because of non-normal dis-
tribution of cost data, all costs were logarithmically trans-
formed to run the three regression models. This transformation
allowed us to use parametric methods and resulted in a model
with better goodness of ﬁt. All P values of o0.05 were considered
signiﬁcant.Results
Of the 1565 stroke cases registered across all participating
hospitals during the study period, we collected data on a total
of 400 patients who met the inclusion criteria over the course of
the study. The sociodemographic and clinical characteristics of
patients are represented in Table 2. The mean age of participating
patients was 61.4  9.4 years, with a predominance of men (62%).
About 43% of the patients consumed tobacco and around 25%
consumed alcohol. Majority of the study population (82.5%)
comprised either homemakers or those who had retired from
the workforce. About 84% of the patients were diagnosed with an
ischemic stroke. Hypertension (53%) and diabetes (40%) were the
most commonly documented risk factors among these patients.
Nearly 7% of the patients had both hypertension and diabetes.
Furthermore, nearly 42.5% of the patients reported severe dis-
ability on the mRS. Death was documented at time of discharge
for 32 patients (8%) who were signiﬁcantly older (79 vs. 61.4 years;
P o 0.001) and were more likely to be women (68.7% vs. 32%;
P o 0.001).
On an average, patients were in the hospital for 16  10 days
for the stroke event and the LOS was not signiﬁcantly differentacross different settings of care. After discharge, most (83%)
patients used follow-up general practitioner services, followed
by specialist visits (65%) and diagnostic procedures (69%). Total
mean health care costs per patient were `504,973 (US $8,020)
(median `455,566; US $7,235) during the ﬁrst year (Table 3). About
47% (mean `235,471; US $3,739) of the total costs were due to
index hospitalization, while outpatient follow-up care accounted
for about 40% of health care costs. Other health care costs related
to nursing care, home modiﬁcations, and informal care
amounted to an average of `69,107 (US $1,098). Although the
magnitude of costs during hospitalization was similar for hem-
orrhagic and ischemic strokes, patients with hemorrhagic stroke
had follow-up health care costs at 3 months postdischarge that
were higher (`92,631 vs. `81,677; P ¼ 0.08) than those of patients
with ischemic stroke. This result, however, was not statistically
signiﬁcant. Cost predictions were further investigated using
multiple regression analysis. Only demographic and clinical
characteristics were used to predict differences in costs. Results
of multiple regression outlined factors that were signiﬁcantly and
positively associated with costs such as being a male patient,
having diabetes, having had a hemorrhagic stroke, and having a
higher mRS score (Table 4). Patients with severe disabilities had
32% higher costs than did patients with moderate disabilities
during the ﬁrst 3 months postdischarge.Discussion
Patients with AF tend to experience more severe strokes, giving
rise to signiﬁcantly increased costs for acute hospitalization due
to more intense and prolonged level of care. The results of the
present multicenter study conducted in India estimate the total
costs of stroke among patients with AF to be `504,273 (US $8,020)
in the ﬁrst year after the event, which are high compared with
the national average annual per capita income of `61,560 (US
$978). The largest contributor of total direct medical cost in the
study was initial hospital LOS during the acute phase of the
event followed by outpatient care during the ﬁrst 3 months
postdischarge.
Table 2 – Baseline sociodemographic and clinical
characteristics of the sample (N ¼ 400).
Characteristic At Baseline
(400)
Deaths
(32)
Mean  SD Mean  SD
Age (y), mean  SD 61.4  9.4 79.1  10.1
n (%) n (%)
Sex
Female 152 (38) 22 (68.7)
Male 248 (62) 10 (31.3)
Employment status
Employed 70 (17.5) – (–)
Retired/other 330 (82.5) 32 (100)
Location
North 127 (31.7) 9 (28.1)
West 154 (38.5) 12 (37.5)
South 119 (29.7) 11 (34.4)
Type of stroke
Ischemic stroke 336 (84) 23 (71.8)
Hemorrhagic stroke 64 (16) 9 (28.2)
Risk factors
Hypertension 212 (53) 21 (65.6)
Diabetes mellitus 160 (40) 17 (53.1)
Hypertension and
diabetes
28 (7) 2 (6.2)
Acute myocardial
infarction
56 (14) 3 (9.4)
Previous stroke or TIA 68 (17) 2 (6.2)
Tobacco consumption 172 (43) 1 (3.1)
Alcohol consumption 99 (24.7) 1 (3.1)
Modiﬁed Rankin Scale
score
Moderate to moderately
severe disability (3–4)
230 (57.5) 14 (43.7)
Severe disability (5) 170 (42.5) 8 (25)
Discharge status
Referred to another
hospital/nursing
home
60 (15) – (–)
Sent home 308 (77) – (–)
Dead 32 (8) – (–)
ICU, intensive care unit; TIA, transient ischemic attack.
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resources used across similar studies. The mean LOS for index
hospitalization in our study was about the same as the mean
number of inpatient days (15  10 days) reported in a study by
Yoon et al. [30] in South Korea as well as in the Berlin Acute
Stroke Study [31]. The LOS reported in our study, however, was
less than the mean LOS (18–20 days) reported in a study by Wei
et al. [32] in China, which can be attributed to differences in
treatment patterns between countries. The mean index hospital-
ization costs reported in this study were similar to the
cost reported in a study by Yoon et al. in South Korea (US
$3,750 vs. US $3,595) [30]. Because there are very few studies that
report the burden of stroke with respect to resource use and costs
in the Asia Paciﬁc region, we compared the results of our study
with data from two European cost-of-illness studies among
patients with AF and stroke using similar methodology.
These studies adopted a societal perspective, with an
incidence-based approach and 1-year follow-up and produced
estimates of €19,953 (`485,140; societal costs) and €20,239
(`552,907; societal costs) per patient per year in Italy andGermany, respectively [32,33]. In addition, this study reported
rehabilitation services to account for about 39% of the total
health care costs in the ﬁrst year postevent, which were similar
to the results reported in a registry study among patients with
stroke in Germany (37%) as well as data reported from an Italian
study (35%) [32–34].
Informal care plays a substantial role in total care provided to
patients with stroke. There are limited data, however, on costs
associated with informal care in developed and developing
countries. In a recent literature review on cost of stroke studies
that used patient-level data, authors showed that only eight (7%)
of the studies included informal care costs [35]. We tried to fulﬁll
the existing gap by providing estimates of informal care costs
determined via structured interviews with patients and care-
givers. Our estimates were much lower than the results of a few
similar studies that showed informal care costs to be a major
component of the total cost of stroke. This could be because the
majority of our sample (comprising of men) reported their wives,
who were homemakers, to be their primary caretakers, thereby
reducing the impact of this resource category on the overall cost
of stroke-related care.
With both its prevalence and the associated death rate
increasing, there is an urgent need to improve the management
of AF, in particular to prevent the most common fatal conse-
quences, such as stroke. Although the current treatment for
stroke with vitamin K antagonists, such as warfarin, can be
effective, it has been well documented that proper dosing
and close monitoring are imperative to attain an optimal
level of anticoagulation to balance the risk of stroke with an
increased risk of bleeding, particularly in elderly patients [36–38].
Effective screening of patients and appropriate anticoagulation
therapy can help prevent many types of AF-related strokes
and improve overall patient outcomes. An interesting ﬁnding of
our study was that only 15% of the patients in our study
sample had received or used any anticoagulation therapy with
warfarin or at least received aspirin before their stroke
event. This highlights the underuse of oral anticoagulation
among this patient population, which could be due to the
increased risk of bleeding, drug and food interactions, and
inconvenience (routine blood monitoring) associated with
warfarin. Newer novel oral anticoagulants, however, have
demonstrated an effective and safe therapeutic proﬁle with
fewer drug/food interactions and no requirements for constant
coagulation monitoring, thereby offering a potential to increase
adherence to therapy and improve outcomes for patients
[27,29,35].
Despite careful design and implementation, our study
presents some limitations. First, the study was conducted at
hospitals located in large urban cities. Patients receiving treat-
ment in these centers belonged to a higher economic class than
do patients living on the outskirts of a city or in rural areas.
Second, the study included both patients with ischemic stroke
and patients with hemorrhagic stroke who had a prior diagnosis
of nonvalvular AF. Hemorrhagic stroke could have been a result
of the anticoagulants the patients were receiving but this infor-
mation could not be teased out from the medical chart records.
Third, the study relied on estimates regarding outpatient
resource use by patients (or their caregivers) and physicians to
calculate cost in the postdischarge period, which could lead to
recall bias and an overestimation or underestimation of cost.
Fourth, because of lack of available data, the study does not
account for resource utilization and costs associated with bleed-
ing events, which could add to the overall economic burden of
stroke. Last, patients dying from stroke early would not have
contributed to the cost estimate because they had to survive at
least the ﬁrst 3 months to contribute to the analysis (immortal
time bias).
Table 3 – Resource utilization and costs during the ﬁrst 12 mo after the stroke event.
Variables % Users Mean  SD
Resources per patient Costs per patient (`)
Total number of days of index hospitalization
(ICU þ general ward days) 100 16  10
Index hospitalization – (–) 235,200  101,857
Outpatient care
GP visits 83 18  1.7 56,294  4,701
Specialist visits 65
Rehabilitation services (physiotherapy, speech therapy) 58 101  35 35,608  18,504
Laboratory visits 34 3.4  6.4 4,000  2,742
Imaging visits 69 5.0  0.3 13,426  5,708
Pharmacotherapy 96 – (–) 91,337  107,809
Total outpatient follow-up care 200,666  110,600
Other costs
Home modiﬁcations 23 – (–) 23,799  10,150
Nursing care (hours per day) 36 9.8  5.2 31,938  12,651
Informal care (hours per day) 25 3.2  1.3 13,370  33,790
Total costs 504,973  152,837
GP, general practitioner; ICU, intensive care unit.
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Because stroke is a life-changing event that affects not only the
person who may be disabled but also his or her family and
caregivers, the overall ﬁnancial burden associated with medical
care for patients with stroke and AF places a signiﬁcant demand
on health services in India. Utility analyses show that a major
stroke is viewed by more than half of those at risk as being
worse than death [36]. Together with loss of time in employ-
ment by the patient as well as the caregiver, stroke adds an
overall signiﬁcant burden on society. A proportion of these
costs may be preventable by lifestyle changes and primary and
secondary prevention programs. This possibility is of para-
mount importance in terms of public health because progres-
sive aging of the population will otherwise cause an increase in
patients with stroke and consequently an increase in health
care expenditure. By laying a foundation for understanding
costs of health care services, data from this study canTable 4 – Multivariate linear regression analyses of factor
3) and 1-y poststroke.
Dependent variable log costs
Independent variable
Age (y)
Sex (female ¼ 1)
Smoker
Previous stroke
Diabetes
Hemorrhagic stroke
Severe disability (mRS score ¼ 5) vs. moderate (mRS score ¼ 3–4)
R2
Adjusted R2
mRS, modiﬁed Rankin Scale.contribute toward making informed decisions on allocation of
scarce resources while maintaining quality care for patients
with stroke. Furthermore, future studies in India should focus
their efforts on understanding the humanistic burden of stroke
on patients and their caregivers because the condition can have
a devastating impact not only on the individual but also his or
her caregivers and family.Acknowledgments
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